C/EBPβ-LIP dually activates glycolysis and the malate aspartate shuttle to maintain NADH/NAD+ homeostasis
Authors:
- Tobias AckermannTATobias Ackermann
- Hidde R. ZuidhofHZHidde R. Zuidhof
- Gertrud KortmanGKGertrud Kortman
- Martijn G. S. RuttenMRMartijn G. S. Rutten
- Mathilde J.C. BroekhuisMBMathilde J.C. Broekhuis
- Mohamad Amr ZainiMZMohamad Amr Zaini
- Goetz HartlebenGHGoetz Hartleben
- Cornelis F. CalkhovenCCCornelis F. Calkhoven
Preprint
Abstract
Oncogene-induced metabolic reprograming supports cell growth and proliferation. Yet, it also links cancer cell survival to certain metabolic pathways and nutrients. In order to synthesise amino acids and nucleotides de novo for growth and proliferation, cancer cells depend on glycolysis, the cytoplasmic oxidation of glucose, which generates necessary metabolic intermediates and ATP. During glycolysis, NAD+ is used as the oxidizing agent and is thereby reduced into NADH. To ensure high glycolysis rates and maintain NADH/NAD+ homeostasis, cytoplasmic NAD+ has to be regenerated. The mitochondria are the major sites of NADH reoxidation into NAD+ where NADH-derived electrons enter the electron transport chain for ATP production. Since NADH/NAD+ cannot cross membranes, the malate-aspartate shuttle (MAS) or the glycerol-3-phosphate shuttle (GPS) are used as intermediate electron carriers. In addition, cytoplasmic NAD+ is generated by NADH-electron transfer to pyruvate, reducing it to lactate (the Warburg effect). NADH/NAD+ homeostasis plays a pivotal role in cancer cell survival, but our knowledge about the involved regulatory mechanisms is still limited. Here, we show that the proto-oncogenic transcription factor C/EBPβ-LIP stimulates both glycolysis and the MAS. Inhibition of glycolysis with ongoing C/EBPβ-LIP-induced MAS activity results in NADH depletion and apoptosis that can be rescued by inhibiting either the MAS or other NADH-consuming processes. Therefore, beyond the discovery of C/EBPβ-LIP as a dual activator of glycolysis and the MAS, this study indicates that simultaneous inhibition of glycolysis and lowering of the NADH/NAD+ ratio may be considered to treat cancer.Keywords
This publication has 36 references indexed in Scilit:
- Imaging Cytosolic NADH-NAD+ Redox State with a Genetically Encoded Fluorescent BiosensorCell Metabolism, 2011
- Apoptosis-Inducing Factor: Structure, Function, and Redox RegulationAntioxidants & Redox Signaling, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Sirtuin regulation of mitochondria: energy production, apoptosis, and signalingTrends in Biochemical Sciences, 2010
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- Targeting aspartate aminotransferase in breast cancerBreast Cancer Research, 2008
- Mice With a Deletion in the Gene for CCAAT/Enhancer-Binding Protein β Are Protected Against Diet-Induced ObesityDiabetes, 2007
- NPM-ALK–dependent expression of the transcription factor CCAAT/enhancer binding protein β in ALK-positive anaplastic large cell lymphomaBlood, 2006
- A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and anaplastic large cell lymphomasBlood, 2005
- Overexpression of C/EBP -LIP, a Naturally Occurring, Dominant-Negative Transcription Factor, in Human Breast CancerJNCI: Journal of the National Cancer Institute, 1997